US 12,486,233 B2
Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
Dana T. Aftab, San Rafael, CA (US); Nathan Guz, Half Moon Bay, CA (US); Stephen Lau, South San Francisco, CA (US); Noel Hamill, Belfast (GB); Tracy Walker, Lurgan (GB); Jana Galbraith, Kinallen (GB); Simon Yau, Sunnyvale, CA (US); and Khalid Shah, Half Moon Bay, CA (US)
Assigned to Exelixis, Inc., Alameda, CA (US)
Filed by Exelixis, Inc., Alameda, CA (US)
Filed on Aug. 2, 2023, as Appl. No. 18/363,994.
Application 17/084,312 is a division of application No. 16/671,834, filed on Nov. 1, 2019, granted, now 10,851,061, issued on Dec. 1, 2020.
Application 16/671,834 is a division of application No. 15/118,738, granted, now 10,501,418, issued on Dec. 10, 2019, previously published as PCT/US2015/016052, filed on Feb. 16, 2015.
Application 18/363,994 is a continuation of application No. 17/212,851, filed on Mar. 25, 2021, granted, now 11,760,726.
Application 17/212,851 is a continuation of application No. 17/084,312, filed on Oct. 29, 2020, granted, now 11,724,986.
Claims priority of provisional application 61/939,985, filed on Feb. 14, 2014.
Prior Publication US 2023/0382867 A1, Nov. 30, 2023
Int. Cl. C07D 215/233 (2006.01); C07D 215/22 (2006.01)
CPC C07D 215/233 (2013.01) [C07D 215/22 (2013.01); C07B 2200/13 (2013.01)] 11 Claims
 
1. A crystalline solid form of Compound 1:

OG Complex Work Unit Chemistry
wherein said crystalline solid form is Form II and said Form II is characterized by an x-ray powder diffraction pattern (CuKα) comprising peaks at 6.4, 8.6, 14.9, and 20.2 (°2θ±0.2° 2θ); or at 11.6, 12.1, 12.6, 12.9, and 14.9 (°2θ±0.2°2θ); or at 6.4, 11.6, 12.1, 12.6, 12.9, 14.8, 14.9, and 20.2 (°2θ±0.2°2θ); or at 6.4, 11.6, 12.1, 12.6, 12.9, 14.8, 14.9, 18.0, 18.8, and 20.2 (°θ0+0.2 °2θ), wherein measurement is at room temperature.